Combination immunotherapy for advanced melanoma after first treatment stops working
Part of Cancer, Immune system & allergy clinical trials.
This trial tests a new combination of two immunotherapy drugs plus a targeted therapy (bevacizumab) for people with advanced melanoma whose cancer continued to grow after previous immunotherapy. The goal is to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced melanoma (stage III or IV) that cannot be removed with surgery.
- Your cancer grew during or after at least two doses of a PD-1/PD-L1 inhibitor (a type of immunotherapy), and this happened within 12 weeks of your last dose.
- If you have BRAF, CKIT, or NRAS gene changes, you must have already tried targeted therapy and it stopped working.
- You are not able to have chemotherapy, or you have refused it.
- You are generally in good health, able to care for yourself, and have a life expectancy of at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three immunotherapy drugs (fianlimab, cemiplimab, and ipilimumab) for people with advanced melanoma that has stopped responding to previous PD-1/PD-L1 treatment. It aims to see if this new combination can help shrink or control the cancer.
This trial tests a new immunotherapy drug (IMC-F106C) combined with standard treatments against the usual nivolumab-based therapy for people with advanced melanoma who have not been treated before. It's for people who carry a specific immune system marker (HLA-A*02:01) and are in fairly good health.
This trial tests a new drug (iSCIB1+) combined with two standard immunotherapy drugs (ipilimumab and nivolumab) as the first treatment for advanced melanoma that cannot be removed by surgery. The goal is to see if adding iSCIB1+ helps the immune system fight the cancer better.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with a chemotherapy drug (albumin-bound paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow cancer growth.
This trial tests a combination of two immunotherapy drugs with standard chemotherapy (bevacizumab, albumin-bound paclitaxel, and carboplatin) for people with advanced acral or mucosal melanoma. The goal is to see if this combination can shrink tumors or slow the cancer's growth better than current treatments.
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
Hear when a new CTLA-4 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.